Topic prioritisation

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Decision date

Decision date

Decision

Decision

Prioritisation programme

Prioritisation programme

Showing 1 to 25 of 389

TitlePrioritisation programmeDecisionDecision date
Fenfluramine for treating seizures associated with Dravet syndrome in people under 2 yearsMedicines evaluationNot selected
Secukinumab for treating moderate to severe hidradenitis suppurativa in people 12 to 17 yearsMedicines evaluationNot selected
Mirikizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 yearsMedicines evaluationNot selected
Bee venom immunotherapy for generalised or systemic IgE-mediated allergic reactions to bee venomMedicines evaluationNot selected
Wasp venom immunotherapy for treating wasp venom allergyMedicines evaluationNot selected
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]Medicines evaluationNot selected
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]Medicines evaluationNot selected
Siponimod for treating multiple sclerosis in people 10 to 17 years [TSID12317]Medicines evaluationNot selected
Pegunigalsidase alfa every 4 weeks for treating Fabry disease [TSID12346]Medicines evaluationNot selected
Peginterferon alfa-2a for treating polycythaemia vera or essential thrombocythaemia [TSID12325]Medicines evaluationNot selected
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]Medicines evaluationNot selected
Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]Medicines evaluationNot selected
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12399]Medicines evaluationNot selected
Dabrafenib with trametinib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12398]Medicines evaluationNot selected
Wireless breast lesion localization using Savi Scout seedInterventional proceduresAwaiting decision
CT hepatic arteriography for patients undergoing percutaneous ablation of primary or secondary liver tumoursInterventional proceduresAwaiting decision
Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312]Medicines evaluationNot selected
Isavuconazol for treating invasive aspergillosis or mucormycosis in people 1 to 17 years [TSID12284]Medicines evaluationNot selected
Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]Medicines evaluationNot selected
SEEG-guided radiofrequency thermocoagulation in refractory epilepsyInterventional proceduresAwaiting decision
Ciclosporin (Vevizye) eye drops for treating moderate to severe keratoconjunctivitis [TSID12293]Medicines evaluationNot selected
Subcutaneous olanzapine for treating schizophrenia [TSID12289]Medicines evaluationNot selected
Menotrophin prefilled pen for treating anovulation or during controlled ovarian hyperstimulation [TSID12290]Medicines evaluationNot selected
Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]None selectedNot selected
Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]None selectedAwaiting decision

Results per page

  1. 10
  2. 25
  3. 50
  4. All